JPH0153254B2 - - Google Patents

Info

Publication number
JPH0153254B2
JPH0153254B2 JP55085232A JP8523280A JPH0153254B2 JP H0153254 B2 JPH0153254 B2 JP H0153254B2 JP 55085232 A JP55085232 A JP 55085232A JP 8523280 A JP8523280 A JP 8523280A JP H0153254 B2 JPH0153254 B2 JP H0153254B2
Authority
JP
Japan
Prior art keywords
tablets
herbal medicine
parts
ultrafine
disintegration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP55085232A
Other languages
Japanese (ja)
Other versions
JPS5711911A (en
Inventor
Yoshimasa Ichio
Hisahiro Uchida
Yoshihiko Akyama
Michio Nagasawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsumura and Co
Original Assignee
Tsumura and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura and Co filed Critical Tsumura and Co
Priority to JP8523280A priority Critical patent/JPS5711911A/en
Publication of JPS5711911A publication Critical patent/JPS5711911A/en
Publication of JPH0153254B2 publication Critical patent/JPH0153254B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は崩壊性良好な漢方薬錠剤の製法に関す
る。 近年、漢方薬が見直され、その需要は急増して
いる。しかるに、漢方薬はその薬臭、味が原因で
敬遠されがちである。この欠点を補う目的で種々
の工夫がなされているが、その1つとして錠剤と
することが考えられている。ところが、漢方薬そ
のままを錠剤とするのでは、その量が多大とな
り、服用しずらい。又、漢方薬のエキスを粉末化
して錠剤とすると少量にはなるが、その錠剤は崩
壊し成分が溶出するのに非常に長時間を要するも
のとなる。つまり漢方薬のエキスをそのまま粉末
化したものを圧縮成型して製した錠剤は水に溶か
そうとする時、崩壊に長時間を要する。これは錠
剤が水にぬれてその表面が粘性の強い膜となり、
この膜がそれ以上水が浸入するのを妨げるからで
ある。 本発明者等は、先にこの欠点を解決した服用し
易く且つ崩壊性良好な漢方薬錠剤の製法として、
漢方薬の抽出液もしくは濃縮液に、超微粒子無水
ケイ酸又は平均孔径が50Å以上の多孔性無水ケイ
酸を、該漢方薬の抽出液もしくはその濃縮液の乾
燥物に対して15〜100%添加、分散させたものを
噴霧乾燥して得た乾燥物を、そのまま、あるいは
適当な賦形剤、滑沢剤と混合し、圧縮成型するこ
とを特徴とする漢方薬錠剤の製法を発明した(特
願昭55−54279号)。 その後、本発明者等は、この製法に関し更に研
究を続けた結果、漢方薬の抽出液もしくはその濃
縮液に加える添加物としては、上記した超微粒子
無水ケイ酸のみならず、一般に水不溶性で無毒性
の超微粒子物であればよく、それを漢方薬の抽出
液もしくはその濃縮液に抽出液し噴霧乾燥して得
た乾燥物を用いて錠剤を製造することにより、崩
壊溶出が極めて速かな錠剤を製造することができ
ることを見い出した。本発明はこの知見に基づく
ものである。 即ち、本発明、漢方薬の抽出液もしくはその濃
縮液に、酸化アルミニウム、酸化チタン、合成ケ
イ酸アルミニウム及びメタケイ酸アルミン酸マグ
ネシウムから選ばれる粒子径数10mμの超微粒子
物を、該漢方薬の抽出液もしくはその濃縮液の乾
燥物に対して15〜100%添加、分散させたものを
噴霧乾燥して得た乾燥物を、そのまま、あるいは
賦形剤、滑沢剤等の適当な添加物と混合し、圧縮
成型することを特徴とする崩壊性良好な漢方薬錠
剤の製法であつて、崩壊溶出が極めて速かな医薬
品として非常に好ましい漢方薬錠剤を得る方法を
提供することを目的とするものである。 以下本発明について詳細に説明する。 本発明で用いる漢方薬には、漢方で言うところ
の漢方薬のみならず、生薬の1種又は2種以上の
混合物からなるいわゆる生薬もしくは生薬製剤も
包含される。 漢方薬の抽出液としては、常法通りに上記の漢
方薬を水で煎出又は浸出したもののみならず、ア
ルコールその他有機溶剤を用いて抽出したものも
用いることができる。 本発明では、この漢方薬の抽出液又はこれを適
当な方法により濃縮した濃縮液に、超微粒子無水
ケイ酸以外の水不溶性で無毒性の超微粒子物を添
加、分散させる。 この水不溶性で無毒性の超微粒子物としては、
超微粒子が凝集体をなすもの(好ましくは平均孔
径が数10mμ以下の超微粒子が凝集体をなすも
の)で、それを漢方薬の抽出液もしくはその濃縮
液に添加し噴霧乾燥した際に、その凝集体の微粒
子間のすきまに漢方薬の成分を取り込むことがで
きる物であれば、何でも良い。その具体例として
は、例えば超微粒子状酸化アルミニウム、超微粒
子状酸化チタン、合成ケイ酸アルミニウム、合成
ケイ酸マグネシウム、合成ケイ酸カルシウム、ケ
イ酸アルミン酸マグネシウム、メタケイ酸アルミ
ン酸マグネシウム等を挙げることができる。 そして上記超微粒子物は単独で又は2種以上を
混合して使用することができる。 上記超微粒子物を添加し噴霧乾燥して得た漢方
薬の抽出液もしくはその濃縮液の乾燥物を用いて
錠剤を製造する時、その錠剤の崩壊が極めて速や
かになるのは、噴霧乾燥して生成する粒子の表面
物性にこれら超微粒子物が関与することによるも
のと考えられる。つまり、漢方薬の抽出液もしく
はその濃縮液に上記の水不溶性で無毒性の超微粒
子物を添加して噴霧乾燥すると、生成する噴霧乾
燥粒子は内部が中空でその表面は超微粒子物、す
なわち超微粒子が多数凝集した凝集体の結合した
ものからなり、しかもこの凝集体の微粒子間のす
きまがあたかも細孔の様に働き、このすきまに漢
方薬の抽出液もしくはその濃縮液の成分が入り込
んだものとなり、このため、この噴霧乾燥粒子を
用いて製造した錠剤は、水にぬれた際、その表面
に粘性の強い膜を作ること無く、速やかに崩壊、
分散するのであろうと推測される。 上記超微粒子物の添加量は、漢方薬の抽出液も
しくはその濃縮液の成分量との関係で決まり、漢
方薬の抽出液もしくはその濃縮液の乾燥物に対し
15〜100%が適当で、好ましくは20〜75%、最適
には25〜50%である。なお、上記超微粒子物の添
加量が少な過ぎれば当然の如く効果が現われない
訳であり、一方多過ぎては服用錠剤量がそれだけ
多くなることとなり好ましくない。かくして添加
量はできるだけ必要最少限にするのが好適であ
り、上記範囲の添加量が適当である。 上記超微粒子物を添加、分散させる手段は、上
記超微粒子物が漢方薬の抽出液もしくはその濃縮
液中に均一に分散できれば如何なる手段を用いて
もよく、例えば適当な撹拌装置を用いて行なうこ
とができる。 上記のようにして、超微粒子物を添加、分散さ
せた漢方薬の抽出液またはその濃縮液の噴霧乾燥
はどの方式の噴霧乾燥機を用いて実施してもよ
く、又、噴霧乾燥条件も常法通りに行えば良い。
例えば送風温度110〜200℃、排風温度90〜160℃
位で行なうことができる。 なお、本発明において、上記のように超微粒子
物を添加、分散させた漢方薬の抽出液またはその
濃縮液を乾燥させる方法は、噴霧乾燥によること
が必須であつて、それ以外の通常の真空凍結乾燥
やタナ式通風乾燥では所期の効果を全く奏さない
ものである。その点を実験例を示して説明すると
次の如くである。 次の試料1〜試料4につき第9改正日本薬局方
の濃縮試験法により崩壊時間を測定した。なお、
試料の製造に用いた超微粒子状酸化チタンは後記
実施例1に記載の超微粒子状酸化チタンと同じも
のである。 試料1:噴霧乾燥する代わりに、真空凍結乾燥
(予め−40℃に凍結した後、タナ加熱温度25℃、
真空度10-2mmHgで行つた)し、乾燥物を粉砕し
て乾燥粉末を得る以外は後記実施例1に記載した
と同様にして製造した八味地黄丸の錠剤。 試料2:八味地黄丸煎出液を減圧下に濃縮する
際に軟エキス状になるまで濃縮し、これに超微粒
子状酸化チタンを添加練合したものをタナ式通風
乾燥(板上に拡げて通風乾燥機にて送風温度50
℃、風速1m/秒の条件で乾燥)し、乾燥物を粉
砕して乾燥粉末を得る以外は、後記実施例1に記
載したと同様にして製造した八味地黄丸の錠剤。 試料3:後記実施例1により製造した八味地黄
丸の錠剤。 試料4:超微粒子状酸化チタンを添加しない以
外は、後記実施例1に記載したと同様にして製造
した八味地黄丸の錠剤。 実験の結果は第1表のとおりである。なお、表
中の崩壊時間は6錠の平均崩壊時間を示す。
The present invention relates to a method for producing Chinese herbal medicine tablets with good disintegration properties. In recent years, Chinese herbal medicine has been reconsidered, and demand for it is rapidly increasing. However, herbal medicines tend to be avoided due to their medicinal odor and taste. Various efforts have been made to compensate for this drawback, and one of them is the use of tablets. However, when Chinese herbal medicines are made into tablets, the amount is large and difficult to take. Furthermore, if the extract of a Chinese herbal medicine is powdered and made into a tablet, the tablet will be in a small amount, but it will take a very long time for the tablet to disintegrate and the ingredients to dissolve. In other words, tablets made by compression molding the powdered extract of Chinese herbal medicine take a long time to disintegrate when trying to dissolve it in water. This happens when the tablet gets wet with water, forming a highly viscous film on its surface.
This is because this membrane prevents further water from entering. The present inventors have previously solved this drawback and developed a method for producing Chinese herbal medicine tablets that are easy to take and have good disintegration properties.
Ultrafine silicic anhydride particles or porous silicic anhydride with an average pore diameter of 50 Å or more are added and dispersed in the extract or concentrate of the herbal medicine at 15 to 100% of the dried extract or concentrate of the herbal medicine. He invented a method for producing Chinese herbal medicine tablets, which is characterized by compressing and molding the dried product obtained by spray-drying the dried product, either as it is or by mixing it with suitable excipients and lubricants (Patent application 1983). −54279). After that, the present inventors continued research on this manufacturing method, and found that not only the above-mentioned ultrafine silicic anhydride but also generally water-insoluble and non-toxic additives can be added to extracts or concentrates of Chinese herbal medicines. Ultrafine particles are sufficient, and tablets can be produced that disintegrates and dissolves extremely quickly by extracting them into a herbal medicine extract or its concentrate and spray-drying the dried product to produce tablets. I found out that it can be done. The present invention is based on this knowledge. That is, according to the present invention, ultrafine particles with a particle diameter of several 10 mμ selected from aluminum oxide, titanium oxide, synthetic aluminum silicate, and magnesium aluminate metasilicate are added to the extract of the herbal medicine or its concentrate. Add 15 to 100% of the concentrated liquid to the dried substance and spray dry the resulting dried substance, which is obtained as it is or mixed with appropriate additives such as excipients and lubricants. The object of the present invention is to provide a method for producing Chinese herbal medicine tablets with good disintegration properties, which are characterized by compression molding, and to provide a method for obtaining Chinese herbal medicine tablets that are highly desirable as pharmaceuticals and disintegrate and dissolve extremely quickly. The present invention will be explained in detail below. The herbal medicine used in the present invention includes not only herbal medicines referred to in Chinese medicine, but also so-called herbal medicines or herbal medicine preparations consisting of one or a mixture of two or more kinds of herbal medicines. As the herbal medicine extract, not only those obtained by decocting or infusing the above-mentioned herbal medicines with water in a conventional manner, but also those extracted using alcohol or other organic solvents can be used. In the present invention, water-insoluble and non-toxic ultrafine particles other than ultrafine silicic anhydride particles are added and dispersed in the extract of this Chinese herbal medicine or a concentrated liquid obtained by concentrating it by an appropriate method. These water-insoluble, non-toxic ultrafine particles include:
It is an aggregate of ultrafine particles (preferably an aggregate of ultrafine particles with an average pore diameter of several tens of microns or less), and when it is added to a Chinese herbal medicine extract or its concentrate and spray-dried, the agglomeration occurs. Any material may be used as long as it can incorporate the components of Chinese herbal medicine into the gaps between the fine particles of the aggregate. Specific examples include ultrafine aluminum oxide, ultrafine titanium oxide, synthetic aluminum silicate, synthetic magnesium silicate, synthetic calcium silicate, magnesium aluminate silicate, magnesium aluminate metasilicate, etc. can. The above-mentioned ultrafine particles can be used alone or in combination of two or more. When manufacturing tablets using a dried herbal medicine extract or concentrate obtained by adding the above-mentioned ultrafine particles and spray-drying, the tablet disintegrates extremely quickly. This is thought to be due to the involvement of these ultrafine particles in the surface properties of the particles. In other words, when the above-mentioned water-insoluble, non-toxic ultrafine particles are added to a Chinese herbal medicine extract or its concentrate and spray-dried, the spray-dried particles that are formed are hollow inside and have ultrafine particles on the surface. It is made up of a combination of a large number of aggregates, and the gaps between the fine particles of these aggregates act like pores, and the components of the herbal medicine extract or its concentrate enter into these gaps. Therefore, when tablets made using these spray-dried particles get wet with water, they quickly disintegrate without forming a highly viscous film on their surface.
It is assumed that it will be dispersed. The amount of the above-mentioned ultrafine particles added is determined in relation to the component amount of the herbal medicine extract or its concentrate, and is based on the amount of the dried herbal medicine extract or its concentrate.
15-100% is suitable, preferably 20-75%, optimally 25-50%. It should be noted that if the amount of the ultrafine particles added is too small, the effect will not be exhibited, while if it is too large, the amount of tablets to be taken will increase accordingly, which is not preferable. Thus, it is preferable to keep the amount added to the minimum necessary amount, and an amount within the above range is appropriate. Any means may be used for adding and dispersing the ultrafine particles as long as the ultrafine particles can be uniformly dispersed in the extract of the Chinese herbal medicine or its concentrate. For example, an appropriate stirring device may be used. can. Spray-drying the herbal medicine extract or its concentrate to which ultrafine particles have been added and dispersed as described above may be carried out using any type of spray dryer, and the spray-drying conditions may be the same as usual. Just go to the street.
For example, the air temperature is 110 to 200℃, and the exhaust temperature is 90 to 160℃.
It can be done in In addition, in the present invention, the method of drying the herbal medicine extract or its concentrate to which ultrafine particles have been added and dispersed as described above must be by spray drying, and other than normal vacuum freezing. Drying or Tana type ventilation drying does not produce the desired effect at all. This point will be explained using an experimental example as follows. The disintegration time was measured for the following samples 1 to 4 using the concentration test method of the 9th revised Japanese Pharmacopoeia. In addition,
The ultrafine titanium oxide used in the production of the sample was the same as the ultrafine titanium oxide described in Example 1 below. Sample 1: Instead of spray drying, vacuum freeze-drying (after freezing to -40℃ in advance, Tana heating temperature 25℃,
Tablets of Hachimijiogan were produced in the same manner as described in Example 1 below, except that the dry powder was obtained by crushing the dried product. Sample 2: When concentrating Hachimijiomaru decoction under reduced pressure, it was concentrated until it became a soft extract, and ultrafine titanium oxide was added to this and kneaded. Blow temperature 50 in a ventilation dryer
Tablets of Hachimijiogan were produced in the same manner as described in Example 1 below, except that the dried product was dried under the conditions of 1 m/sec at a wind speed of 1 m/sec) and pulverized to obtain a dry powder. Sample 3: Hachimijiogan tablet manufactured according to Example 1 described below. Sample 4: A tablet of Hachimijiogan produced in the same manner as described in Example 1 below, except that ultrafine titanium oxide was not added. The results of the experiment are shown in Table 1. Note that the disintegration time in the table indicates the average disintegration time of 6 tablets.

【表】 第1表の結果から、乾燥法を噴霧乾燥以外の真
空凍結乾燥やタナ式通風乾燥とした場合は、無水
ケイ酸無添加の試料4と同程度に錠剤の崩壊に長
時間を要し、崩壊性向上の効果が全く見られない
ことが認められる。 上記のようにして得られた乾燥粉末は、そのま
ま圧縮成型しても良いし、又、必要に応じて賦形
剤、滑沢剤等の適当な添加物、例えば乳糖、ブド
ウ等、マンニツト等の糖類、コーンスターチ、ポ
テトスターチ等の澱粉類とこれらの加工品、微結
晶セルロース、繊維素グリコール酸ナトリウム等
のセルロース系物質、およびリン酸水素カルシウ
ム、ステアリン酸マグネシウム等の無機塩類など
を添加してから圧縮成型することもできる。 本発明により製造した漢方薬錠剤は、従来のも
のに比べその崩壊性が良好であり、溶解吸収性が
極めて優れたものである。又、副次的効果とし
て、錠剤表面の変色等の経時変化も起り難く、医
薬品として極めて好ましいものである。 以下、実施例を挙げて本発明をさらに具体的に
説明するが、本発明はこれにより制限されるもの
ではない。 実施例 1 八味地黄丸(地黄6部、沢瀉3部、茯苓3部、
牡丹皮2.5部、柱枝1部、山薬3部、山茉萸3部、
加工ブシ0.5部より成る)の処方生薬5Kgを常法
通りに水50で煎じ、かすを去つた後、減圧下40
℃で約1/5に濃縮する。この液3.5(乾燥物700
g)を取り、超微粒子状酸化チタン〔「Titanium
Oxide P25」日本アエロジル株式会社製商品(超
微粒子の平均粒子径約30mμ)〕を300g添加し、
プロペラ式撹拌機にて撹拌分散させる。この液を
噴霧乾燥(送風温度150℃、排風温度100℃)して
約800gの乾燥粉末を得た。この粉末99.5部にマ
グネシウムステアレート0.5部を混合し、1錠が
300mgになるように圧縮成型して八味地黄丸の錠
剤を得た。 ここに製造した八味地黄丸の錠剤は、下記の崩
壊試験では平均15.1分と極めて速やかに崩壊し、
速やかに成分を溶出した。これに対し、上記超微
粒子状酸化チタンを添加するかわりに通常の顔料
用酸化チタン(平均粒子径0.5μ)を添加して上記
と同様にして製造した八味地黄丸の錠剤の崩壊時
間は57.2分であつた。又、上記超微粒子状酸化チ
タンを添加しない以外は上記したと同様して製造
した八味地黄丸の錠剤の崩壊時間は69.3分であつ
た。 なお崩壊時間は第9改正日本薬局方の崩壊試験
法にしたがつて測定した。即ち、内径22mmの両端
が開口したガラス管の下端を網目の開き2.0mmの
網でふさぎ、その網の上に試料の錠剤を1ケ置
き、このガラス管を蒸留水に浸けて上下させ網上
に残留物を認めなくなつた時を崩壊終了として崩
壊時間とした。なお又、崩壊時間はそれぞれ6錠
の平均時間で表わしたものである。 実施例 2 超微粒子状酸化チタンの代りに超微粒子状酸化
アルミニウム〔「Aluminium Oxide C」日本ア
エロジル株式会社製商品(超微粒子の平均粒子径
約20mμ)〕を用いる以外は、実施例1に記載し
たと同様に実施して八味地黄丸の錠剤を得た。 この錠剤は、前述の崩壊試験では平均14.7分で
崩壊し、速かに成分を溶出した。これに対し、上
記超微粒子状酸化アルミニウムを添加しない以外
は、上記したと同様にして製造した八味地黄丸の
錠剤の崩壊時間は前述したように平均69.3分であ
つた。 実施例 3 安中散(柱皮4部、延胡索3部、牡蠣3部、茴
香1.5部、縮砂1部、甘草1部、良姜0.5部)の処
方生薬5Kgを常法通りに水50で煎じ、かすを去
つた後、減圧下40℃で約1/5に濃縮する。この液
5(乾燥物750g)を取り、メタケイ酸アルミ
ン酸マグネシウム〔「ノイシリンUFL2」富士化
学工業株式会社製商品(超微粒子の平均粒子径約
20mμ)〕を250g添加し、撹拌分散させる。この
液を噴霧乾燥(送風温度160℃、排風温度110℃)
して約900gの乾燥粉末を得た。この粉末99.5部
にマグネシウムステアレート0.5部を混合し、1
錠が300mgになるように圧縮成型し安中散の錠剤
を得た。 ここに製造した安中散の錠剤は、前述した崩壊
試験では平均17.2分と極めて速やかに崩壊し、速
やかに成分を溶出した。これに対し、上記メタケ
イ酸アルミン酸マグネシウムを添加しない以外
は、上記したと同様にして製造した安中散の錠剤
の崩壊時間は平均81.5分であつた。 実施例 4 大柴胡湯(柴胡6部、半夏4部、黄〓3部、芍
薬3部、大棗3部、枳実2部、乾生姜1部、大黄
1部)の処方生薬5Kgを常法通りに水75で煎
じ、かすを去つた後、減圧下40℃で約1/6に濃縮
する。この液5(乾燥物800g)を取り、合成
ケイ酸アルミニウム(「合成ケイ酸アルミニウム
特軽質」協和化工業株式会社製商品)を400g添
加し、撹拌分散させる。以下、実施例1に記載し
たと同様に噴霧乾燥して約1Kgの乾燥粉末を得
た。この粉末99.5部にアルミニウムステアレート
0.5部を混合し、1錠が250mgになるように圧縮成
型して大柴胡湯の錠剤を得た。 ここに製造した大柴胡湯の錠剤は、前述した崩
壊試験で試験したところ、平均12.4分と極めて速
やかに崩壊し、速やかに成分を溶出した。これに
対し、上記合成ケイ酸アルミニウムを添加しない
以外は、上記したと同様にして製造した大柴胡湯
の錠剤の崩壊時間は平均65.1分であつた。 実施例 5 薬用人参5Kgを常法通りに水50で煎じ、かす
を去つた後、減圧下40℃で約1/4に濃縮する。こ
の液4(乾燥物750)を取り、実施例3に記
載したメタケイ酸アルミン酸アルミニウムを150
g添加し、撹拌分散させる。この液を噴霧乾燥
(送風温度160℃、排風温度105℃)して約800gの
乾燥粉末を得た。この粉末を1錠が200mgになる
ように圧縮成型して薬用人参の錠剤を得た。 この錠剤は、前述の崩壊試験で試験したとこ
ろ、平均21.5分で崩壊し、速やかに成分を溶出し
た。これに対し、上記メタケイ酸アルミン酸マグ
ネシウムを添加しない以外は、上記したと同様に
して製造した薬用人参の錠剤は、前述した崩壊試
験で試験したところ、平均47.3分の崩壊時間を示
した。 実施例 6 実施例3に記載したと同様にして噴霧乾燥して
得た粉末69.5部に微結晶セルロース25.0部とマグ
ネシウムステアレート0.5部を混合し、1錠が350
mgになるように圧縮成型して安中散の錠剤を得
た。 ここに製造した安中散の錠剤は、前述した崩壊
試験で試験したところ、平均14.3分で崩壊し、速
やかに成分を溶出した。これに対し、メタケイ酸
アルミン酸マグネシウム〔「ノイシリンUFL2
(富士化学工業株式会社製商品(超微粒子の平均
粒子径約20mμ)〕を添加しない以外は、上記と
同様にして製造した安中散の錠剤は、前述した崩
壊試験で試験したところ、59.7分の崩壊時間を要
した。
[Table] From the results in Table 1, it can be seen that when the drying method is vacuum freeze drying or TANA air drying other than spray drying, it takes a long time for the tablets to disintegrate, which is the same as Sample 4 without the addition of silicic anhydride. However, it was observed that no effect of improving disintegration property was observed. The dry powder obtained as described above may be compression molded as is, or if necessary, suitable additives such as excipients and lubricants may be added, such as lactose, grapes, mannitol, etc. After adding sugars, starches such as corn starch and potato starch, processed products thereof, cellulose substances such as microcrystalline cellulose and sodium cellulose glycolate, and inorganic salts such as calcium hydrogen phosphate and magnesium stearate, etc. It can also be compression molded. The herbal medicine tablets produced according to the present invention have better disintegration properties than conventional ones and extremely excellent dissolution and absorption properties. In addition, as a side effect, changes over time such as discoloration of the tablet surface are less likely to occur, making it extremely desirable as a pharmaceutical product. EXAMPLES Hereinafter, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited thereto. Example 1 Hachimijiogan (6 parts of Jianjiang, 3 parts of Sawatan, 3 parts of Bulyo,
2.5 parts of peony bark, 1 part of twigs, 3 parts of wild medicine, 3 parts of wild mushrooms,
Decoct 5 kg of prescribed herbal medicine (consisting of 0.5 parts of processed bush) with 50 kg of water in the usual manner, remove the residue, and boil under reduced pressure for 40 kg.
Concentrate to approximately 1/5 at °C. This liquid 3.5 (dry matter 700
g) and ultrafine particle titanium oxide [Titanium
Add 300g of "Oxide P25" manufactured by Nippon Aerosil Co., Ltd. (average particle size of ultrafine particles approximately 30mμ)],
Stir and disperse using a propeller type stirrer. This liquid was spray-dried (blow temperature: 150°C, exhaust air temperature: 100°C) to obtain about 800 g of dry powder. Mix 99.5 parts of this powder with 0.5 parts of magnesium stearate to make one tablet.
The tablets of Hachimijiogan were obtained by compression molding to 300 mg. The Hachimijiogan tablets manufactured here disintegrated extremely quickly, taking an average of 15.1 minutes in the following disintegration test.
The components were quickly eluted. On the other hand, the disintegration time of Hachimijiogan tablets produced in the same manner as described above by adding ordinary titanium oxide for pigments (average particle size 0.5μ) instead of adding the ultrafine particulate titanium oxide was 57.2 It was hot in minutes. Furthermore, the disintegration time of the Hachimijiogan tablets produced in the same manner as above except that the ultrafine particulate titanium oxide was not added was 69.3 minutes. The disintegration time was measured according to the disintegration test method of the 9th edition of the Japanese Pharmacopoeia. That is, the lower end of a glass tube with an inner diameter of 22 mm and open ends was covered with a mesh with a mesh opening of 2.0 mm, one sample tablet was placed on the mesh, and the glass tube was immersed in distilled water and moved up and down onto the mesh. The time when no residue was observed was defined as the end of the disintegration and the disintegration time. Furthermore, each disintegration time is expressed as the average time of 6 tablets. Example 2 The same procedure as described in Example 1 was used, except that ultrafine aluminum oxide ["Aluminum Oxide C", a product manufactured by Nippon Aerosil Co., Ltd. (average particle diameter of ultrafine particles, about 20 mμ)] was used instead of ultrafine titanium oxide. The procedure was carried out in the same manner as above to obtain Hachimijiogan tablets. This tablet disintegrated in an average of 14.7 minutes in the disintegration test described above, and the ingredients were rapidly eluted. On the other hand, the average disintegration time of the Hachimijiogan tablets produced in the same manner as described above, except that the ultrafine particulate aluminum oxide was not added, was 69.3 minutes as described above. Example 3 5 kg of the prescribed herbal medicine Annachusan (4 parts of pillar bark, 3 parts of oysters, 1.5 parts of oyster, 1 part of fried sand, 1 part of licorice, 0.5 parts of ginger) was mixed with 50 g of water in the usual manner. After decoction and removing the residue, concentrate to about 1/5 at 40℃ under reduced pressure. Take this liquid 5 (750 g of dry matter) and use magnesium aluminate metasilicate ["Neusilin UFL 2 ", a product manufactured by Fuji Chemical Industry Co., Ltd. (average particle diameter of ultrafine particles, approx.
20mμ)] and stir to disperse. Spray dry this liquid (blow temperature 160℃, exhaust temperature 110℃)
About 900 g of dry powder was obtained. 0.5 parts of magnesium stearate was mixed with 99.5 parts of this powder, and 1
The tablets were compressed and molded to a size of 300 mg to obtain Annachusan tablets. The Anchusan tablets produced here disintegrated extremely quickly in the disintegration test described above, taking an average of 17.2 minutes, and the ingredients were rapidly eluted. On the other hand, the average disintegration time of Annachusan tablets produced in the same manner as described above, except that the above-mentioned magnesium aluminate metasilicate was not added, was 81.5 minutes. Example 4 A patient regularly took 5 kg of the prescribed herbal medicine Daisaikoto (6 parts Saiko, 4 parts Hanxia, 3 parts Huang, 3 parts Peony, 3 parts Daijutsu, 2 parts Junji, 1 part dried ginger, 1 part Rhubarb). Decoct with 75% water according to the method, remove the residue, and concentrate to about 1/6 at 40℃ under reduced pressure. Take this liquid 5 (800 g of dry matter), add 400 g of synthetic aluminum silicate ("synthetic aluminum silicate extra light" product manufactured by Kyowa Kakogyo Co., Ltd.), and stir and disperse. Thereafter, spray drying was carried out in the same manner as described in Example 1 to obtain about 1 kg of dry powder. 99.5 parts of this powder contains aluminum stearate
0.5 parts were mixed and compression molded so that each tablet weighed 250 mg to obtain Daisaikoto tablets. When the Daisaikoto tablets produced here were tested in the disintegration test described above, they disintegrated very quickly, taking an average of 12.4 minutes, and the ingredients were rapidly eluted. In contrast, the average disintegration time of the Daisaikoto tablets produced in the same manner as described above, except that the synthetic aluminum silicate was not added, was 65.1 minutes. Example 5 5kg of medicinal ginseng is decocted with 50% of water in a conventional manner, and after removing the residue, it is concentrated to about 1/4 at 40°C under reduced pressure. Take this liquid 4 (dry product 750%) and add aluminum metasilicate aluminate described in Example 3 to 150%
g and stir to disperse. This liquid was spray-dried (blow temperature: 160°C, exhaust temperature: 105°C) to obtain about 800 g of dry powder. This powder was compressed and molded so that each tablet weighed 200 mg to obtain medicinal ginseng tablets. When this tablet was tested in the disintegration test described above, it disintegrated in an average of 21.5 minutes, and the ingredients were rapidly eluted. On the other hand, when the medicinal ginseng tablets produced in the same manner as described above except for not adding the magnesium aluminate metasilicate were tested in the disintegration test described above, they showed an average disintegration time of 47.3 minutes. Example 6 69.5 parts of a powder obtained by spray drying in the same manner as described in Example 3 was mixed with 25.0 parts of microcrystalline cellulose and 0.5 parts of magnesium stearate, and one tablet contained 350
The tablets were compressed to give Annachusan tablets. When the Anchusan tablets produced here were tested in the disintegration test described above, they disintegrated in an average of 14.3 minutes, and the ingredients were rapidly eluted. On the other hand, magnesium aluminate metasilicate [“Neusilin UFL 2 ”]
(A product manufactured by Fuji Chemical Industry Co., Ltd. (average particle diameter of ultrafine particles of approximately 20 mμ))] Anchusan tablets manufactured in the same manner as above were tested in the disintegration test described above, and it took 59.7 minutes. It took a long time to collapse.

Claims (1)

【特許請求の範囲】[Claims] 1 漢方薬の抽出液もしくはその濃縮液に、酸化
アルミニウム、酸化チタン、合成ケイ酸アルミニ
ウム及びメタケイ酸アルミン酸マグネシウムから
選ばれる粒子径数10mμの超微粒子物を、該漢方
薬の抽出液もしくはその濃縮液の乾燥物に対して
15〜100%添加、分散させたものを噴霧乾燥して
得た乾燥物を、そのまま、あるいは賦形剤、滑沢
剤等の適当な添加物と混合し、圧縮成形すること
を特徴とする崩壊性良好な漢方薬錠剤の製法。
1 Add ultrafine particles with a particle diameter of several 10 mμ selected from aluminum oxide, titanium oxide, synthetic aluminum silicate, and magnesium aluminate metasilicate to the extract or concentrate of the herbal medicine. for dry matter
Disintegration characterized by compression molding the dried product obtained by spray drying a 15 to 100% added and dispersed product, either as it is or by mixing it with appropriate additives such as excipients and lubricants. A method for producing Chinese herbal medicine tablets with good properties.
JP8523280A 1980-06-25 1980-06-25 Preparation of herb medicine tablet Granted JPS5711911A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8523280A JPS5711911A (en) 1980-06-25 1980-06-25 Preparation of herb medicine tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8523280A JPS5711911A (en) 1980-06-25 1980-06-25 Preparation of herb medicine tablet

Publications (2)

Publication Number Publication Date
JPS5711911A JPS5711911A (en) 1982-01-21
JPH0153254B2 true JPH0153254B2 (en) 1989-11-13

Family

ID=13852810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8523280A Granted JPS5711911A (en) 1980-06-25 1980-06-25 Preparation of herb medicine tablet

Country Status (1)

Country Link
JP (1) JPS5711911A (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2626975B2 (en) * 1987-03-30 1997-07-02 エーザイ株式会社 Tablets containing low-melting oily substances
JPH01165527A (en) * 1987-12-23 1989-06-29 Tsumura & Co Preparation of extract of chinese medicine
DE69207656T2 (en) * 1991-01-30 1996-10-17 Wellcome Found WATER-SOLUBLE TABLETS
JP4750242B2 (en) * 2000-04-14 2011-08-17 木村産業株式会社 Granulated product and tablet production method
JP2002326925A (en) * 2001-04-27 2002-11-15 Asahi Breweries Ltd Method for producing pellet and tablet
JP5718714B2 (en) * 2011-04-20 2015-05-13 ロート製薬株式会社 Pharmaceutical composition

Also Published As

Publication number Publication date
JPS5711911A (en) 1982-01-21

Similar Documents

Publication Publication Date Title
US4835187A (en) Spray dried ibuprofen
JP5240822B2 (en) Porous cellulose aggregate and molded body composition thereof
JPH11500441A (en) Use of inorganic aerogels in pharmacy
WO2013180248A1 (en) Cellulose powder
TW200538162A (en) Porous cellulose aggregate and molded composition thereof
JP5759113B2 (en) Extract powder combination tablets
CN104379605B (en) Cellulose powder
Tobyn et al. Prediction of physical properties of a novel polysaccharide controlled release system. I
JPH0153254B2 (en)
JP3961596B2 (en) Inorganic antacid containing fast dispersible granule, method for producing the same, and suspended internal antacid
JP4750242B2 (en) Granulated product and tablet production method
CN102085344B (en) Aplotaxis carminative sustained-release preparation and preparation method thereof
CN100488493C (en) Antelope horn fast dispersion solid preparation for clearing lung
JPH0153253B2 (en)
US20040146563A1 (en) Granulated product and process for producing tablets
JP6272432B2 (en) Granulated product containing Kamitsumonoyu extract powder
CN100384405C (en) Hepatitis B support right fast dispersion solid preparation and its preparation method
JPS61282319A (en) Production of chinese herb extract
JPH0595988A (en) Herb extract granule and preparation of solid drug containing herb extract
JPH0322370B2 (en)
CN100384402C (en) Jinsang sanjie fast dispersion solid preparation for treating throat and its preparation method
JPH05507651A (en) Active substance bound in a releasable manner
CN109700773A (en) A kind of ticagrelor preparation compositions and preparation method thereof
JPS587608B2 (en) Manufacturing method for Chinese herbal medicine hard capsules
CN109939237A (en) Preparation method containing Montelukast Sodium oral disintegrating tablet